VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.840
+0.030 (3.70%)
Nov 21, 2024, 2:39 PM EST - Market open

Company Description

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally.

The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

VolitionRx Limited is based in Henderson, Nevada.

VolitionRx Limited
VolitionRx logo
Country United States
Industry Diagnostics & Research
Sector Healthcare
Employees 110
CEO Cameron Reynolds

Contact Details

Address:
1489 West Warm Springs Road, Suite 110
Henderson, Nevada 89014
United States
Phone 646 650 1351
Website volition.com

Stock Details

Ticker Symbol VNRX
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000093314
CUSIP Number 928661107
ISIN Number US9286611077
Employer ID 91-1949078
SIC Code 2835

Key Executives

Name Position
Dr. Salvatore Thomas Butera DVM Chief Executive Officer of Volition Veterinary Diagnostics Development LLC
Cameron Reynolds MBA Founder, Chief Executive Officer, President and Director
Dr. Gaetan Michel Ph.D. Chief Operating Officer
Terig Hughes Chief Financial Officer and Treasurer
Dr. Jacob Vincent Micallef MBA, Ph.D. Chief Scientific Officer
Nicholas Plummer Group General Counsel
Louise Batchelor Day Group Chief Marketing and Communications Officer
Gael Forterre M.B.A. Chief Commercial Officer
Sharon Ballesteros U.S. Head of Quality and Development Process
Dr. Andrew Retter MBBS Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 14, 2024 10-Q Quarterly Report
Nov 14, 2024 8-K Current Report
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 S-3 Registration statement under Securities Act of 1933
Nov 6, 2024 8-K Current Report
Sep 30, 2024 8-K Current Report
Sep 27, 2024 8-K Current Report
Sep 16, 2024 8-K Current Report
Aug 14, 2024 10-Q Quarterly Report